Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ONGLYZA

SAXAGLIPTIN HYDROCHLORIDE

Standard Dose
EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ONGLYZA is listed in Drugs@FDA under application 022350 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SAXAGLIPTIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-10-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview ONGLYZA is listed in Drugs@FDA under application 022350 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SAXAGLIPTIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-10-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ONGLYZA (SAXAGLIPTIN HYDROCHLORIDE) | Drug Monograph | MedicHelpline